Sei Investments Co. lifted its stake in shares of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) by 1,695.3% in the second quarter, according to the company in its most recent filing with the SEC. The fund owned 506,429 shares of the specialty pharmaceutical company’s stock after buying an additional 478,220 shares during the quarter. Sei Investments Co.’s holdings in AMAG Pharmaceuticals were worth $9,876,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of AMAG. State of Wisconsin Investment Board boosted its stake in shares of AMAG Pharmaceuticals by 34.6% in the 2nd quarter. State of Wisconsin Investment Board now owns 35,000 shares of the specialty pharmaceutical company’s stock valued at $682,000 after purchasing an additional 9,000 shares during the last quarter. Alps Advisors Inc. lifted its position in shares of AMAG Pharmaceuticals by 9.0% during the 2nd quarter. Alps Advisors Inc. now owns 49,816 shares of the specialty pharmaceutical company’s stock valued at $971,000 after acquiring an additional 4,096 shares during the period. First Trust Advisors LP lifted its position in shares of AMAG Pharmaceuticals by 106.8% during the 2nd quarter. First Trust Advisors LP now owns 70,869 shares of the specialty pharmaceutical company’s stock valued at $1,382,000 after acquiring an additional 36,607 shares during the period. Massachusetts Financial Services Co. MA lifted its position in shares of AMAG Pharmaceuticals by 15.9% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 94,508 shares of the specialty pharmaceutical company’s stock valued at $1,842,000 after acquiring an additional 12,944 shares during the period. Finally, Piedmont Investment Advisors LLC acquired a new position in shares of AMAG Pharmaceuticals during the 2nd quarter valued at $156,000.

In other news, CEO William K. Heiden sold 5,000 shares of the company’s stock in a transaction on Tuesday, August 7th. The shares were sold at an average price of $25.00, for a total value of $125,000.00. Following the completion of the sale, the chief executive officer now owns 328,015 shares in the company, valued at approximately $8,200,375. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO William K. Heiden sold 20,000 shares of the company’s stock in a transaction on Monday, June 4th. The stock was sold at an average price of $25.00, for a total transaction of $500,000.00. Following the completion of the sale, the chief executive officer now owns 333,015 shares of the company’s stock, valued at approximately $8,325,375. The disclosure for this sale can be found here. Corporate insiders own 4.00% of the company’s stock.

AMAG opened at $24.10 on Tuesday. The company has a current ratio of 2.06, a quick ratio of 1.95 and a debt-to-equity ratio of 0.99. AMAG Pharmaceuticals, Inc. has a 1-year low of $11.93 and a 1-year high of $26.10.

AMAG Pharmaceuticals (NASDAQ:AMAG) last released its quarterly earnings data on Thursday, August 2nd. The specialty pharmaceutical company reported ($0.75) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.21) by ($0.54). AMAG Pharmaceuticals had a negative return on equity of 2.77% and a negative net margin of 36.87%. The business had revenue of $146.25 million for the quarter, compared to analyst estimates of $156.26 million. During the same quarter in the previous year, the company posted ($0.40) EPS. The business’s quarterly revenue was up 12.2% on a year-over-year basis. equities research analysts forecast that AMAG Pharmaceuticals, Inc. will post -3.31 earnings per share for the current year.

AMAG has been the topic of a number of research reports. BidaskClub downgraded shares of AMAG Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Monday, May 28th. Leerink Swann initiated coverage on shares of AMAG Pharmaceuticals in a research report on Monday, May 21st. They set a “market perform” rating and a $24.65 target price on the stock. ValuEngine upgraded shares of AMAG Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, June 6th. Jefferies Financial Group reiterated a “hold” rating and set a $22.00 target price on shares of AMAG Pharmaceuticals in a research report on Friday, August 3rd. Finally, B. Riley upgraded shares of AMAG Pharmaceuticals from a “neutral” rating to a “buy” rating and boosted their target price for the company from $23.00 to $30.00 in a research report on Friday, June 15th. Eight equities research analysts have rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. AMAG Pharmaceuticals presently has a consensus rating of “Hold” and an average price target of $22.97.

AMAG Pharmaceuticals Profile

AMAG Pharmaceuticals, Inc, a biopharmaceutical company, manufactures, develops, and commercializes therapeutics for maternal and women's health, anemia management, and cancer supportive care in the United States. It markets Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, as well as patients who have chronic kidney disease; Intrarosa(prasterone) vaginal insert steroid for the treatment of dyspareunia due to menopause; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds.

Further Reading: Market Capitalization

Want to see what other hedge funds are holding AMAG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG).

Institutional Ownership by Quarter for AMAG Pharmaceuticals (NASDAQ:AMAG)

Receive News & Ratings for AMAG Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.